These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 21979907)

  • 1. [Value of nerve growth factor levels in overactive bladder syndrome: alterations after botulinum toxin therapy].
    Knippschild S; Frohme C; Olbert P; Hofmann R; Hegele A
    Urologe A; 2012 Mar; 51(3):379-83. PubMed ID: 21979907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in prostaglandin E2 in patients with idiopathic overactive bladder syndrome after botulinum toxin type A treatment: is there a clinical benefit?
    Hegele A; Knippschild S; Frohme C; Hänze J; Olbert P; Hofmann R
    BMC Urol; 2014 Nov; 14():85. PubMed ID: 25370343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nerve growth factor (NGF): a potential urinary biomarker for overactive bladder syndrome (OAB)?
    Seth JH; Sahai A; Khan MS; van der Aa F; de Ridder D; Panicker JN; Dasgupta P; Fowler CJ
    BJU Int; 2013 Mar; 111(3):372-80. PubMed ID: 23444927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of botulinum toxin-A in refractory idiopathic overactive bladder patients without detrusor overactivity.
    Kanagarajah P; Ayyathurai R; Caruso DJ; Gomez C; Gousse AE
    Int Urol Nephrol; 2012 Feb; 44(1):91-7. PubMed ID: 21643644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased serum nerve growth factor levels in patients with overactive bladder syndrome refractory to antimuscarinic therapy.
    Liu HT; Lin H; Kuo HC
    Neurourol Urodyn; 2011 Nov; 30(8):1525-9. PubMed ID: 21826717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcomes of intravesical injections of botulinum toxin type A in patients with refractory idiopathic overactive bladder.
    Juszczak K; Adamczyk P; Maciukiewicz P; Drewa T
    Pharmacol Rep; 2018 Dec; 70(6):1133-1138. PubMed ID: 30317128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors Associated with Therapeutic Efficacy of Intravesical OnabotulinumtoxinA Injection for Overactive Bladder Syndrome.
    Hsiao SM; Lin HH; Kuo HC
    PLoS One; 2016; 11(1):e0147137. PubMed ID: 26824901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urinary nerve growth factor in women with overactive bladder syndrome.
    Liu HT; Chen CY; Kuo HC
    BJU Int; 2011 Mar; 107(5):799-803. PubMed ID: 20804479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Botulinum toxin injections for adults with overactive bladder syndrome.
    Duthie JB; Vincent M; Herbison GP; Wilson DI; Wilson D
    Cochrane Database Syst Rev; 2011 Dec; (12):CD005493. PubMed ID: 22161392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NGF and HB-EGF: potential biomarkers that reflect the effects of fesoterodine in patients with overactive bladder syndrome.
    Kim SR; Moon YJ; Kim SK; Bai SW
    Yonsei Med J; 2015 Jan; 56(1):204-11. PubMed ID: 25510766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased serum adipokines implicate chronic inflammation in the pathogenesis of overactive bladder syndrome refractory to antimuscarinic therapy.
    Liu HT; Jiang YH; Kuo HC
    PLoS One; 2013; 8(10):e76706. PubMed ID: 24098552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes of urinary nerve growth factor and prostaglandins in male patients with overactive bladder symptom.
    Kim JC; Park EY; Hong SH; Seo SI; Park YH; Hwang TK
    Int J Urol; 2005 Oct; 12(10):875-80. PubMed ID: 16323980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of refractory idiopathic overactive bladder: intradetrusor injection of botulinum toxin type A versus posterior tibial nerve stimulation.
    Sherif H; Khalil M; Omar R
    Can J Urol; 2017 Jun; 24(3):8838-8846. PubMed ID: 28646940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Objective and subjective improvement in children with idiopathic detrusor overactivity after intravesical botulinum toxin injection: A preliminary report.
    Al Edwan GM; Mansi HH; Atta ONM; Shaath MM; Al Adwan R; Mahafza W; Afram KM; Ababneh O; Al Adwan D; Muheilan MM
    J Pediatr Surg; 2019 Mar; 54(3):595-599. PubMed ID: 29887168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in urinary nerve growth factor and prostaglandin E2 in women with overactive bladder after anticholinergics.
    Cho KJ; Kim HS; Koh JS; Kim JC
    Int Urogynecol J; 2013 Feb; 24(2):325-30. PubMed ID: 22717785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of urinary nerve growth factor level with pathogenesis of overactive bladder.
    Yokoyama T; Kumon H; Nagai A
    Neurourol Urodyn; 2008; 27(5):417-20. PubMed ID: 17924444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effects of botulinum toxin type A in the single and repeated treatment of overactive bladder. A prospective analysis].
    Frohme C; Varga Z; Olbert P; Schrader AJ; Hofmann R; Hegele A
    Urologe A; 2010 May; 49(5):639-44. PubMed ID: 20182692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urinary nerve growth factor levels in overactive bladder syndrome and lower urinary tract disorders.
    Liu HT; Chen CY; Kuo HC
    J Formos Med Assoc; 2010 Dec; 109(12):862-78. PubMed ID: 21195884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Pharmacological Mechanism of Diabetes Mellitus-Associated Overactive Bladder and Its Treatment with Botulinum Toxin A.
    Wang CC; Jiang YH; Kuo HC
    Toxins (Basel); 2020 Mar; 12(3):. PubMed ID: 32188046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repeated botulinum toxin injection for idiopathic overactive bladder: will chemodenervation become a long-term solution?
    Unwala DJ; Barboglio P; Gousse AE
    Curr Urol Rep; 2007 Sep; 8(5):419-24. PubMed ID: 17880843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.